A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma

Blood Adv. 2023 Nov 14;7(21):6785-6789. doi: 10.1182/bloodadvances.2023010653.

Authors

Paolo Strati¹, Andrew Jallouk¹, Qing Deng¹, Xubin Li¹, Lei Feng², Ryan Sun², Sherry Adkins¹, Swapna Johncy¹, Taylor Cain¹, Raphael E Steiner¹, Sairah Ahmed¹, Dai Chihara¹, Luis E Fayad¹, Swaminathan P Iyer¹, Sandra Horowitz¹, Loretta J Nastoupil¹, Ranjit Nair¹, Ahmed Hassan³, Taher E Daoud³, Misha Hawkins¹, Maria A Rodriguez¹, Elizabeth J Shpall⁴, Jeremy L Ramdial⁴, Partow Kebriaei⁴, David S Hong⁵, Jason R Westin¹, Sattva S Neelapu¹, Michael R Green¹

Affiliations

¹ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
³ Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
⁴ Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
⁵ Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Publication types

Clinical Trial, Phase I

MeSH terms

Humans
Immunotherapy, Adoptive
Interleukin 1 Receptor Antagonist Protein* / therapeutic use
Lymphoma, Large B-Cell, Diffuse* / drug therapy

Substances

Interleukin 1 Receptor Antagonist Protein

Grants and funding